Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enoxaparin sodium [679809-58-6]
Cat# T22323-200mg
Size : 200mg
Marca : TargetMol
Enoxaparin sodium
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.
Description | Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots. |
Molecular Weight | 1322 |
Formula | C42H59N3Na4O35S2 |
CAS No. | 679809-58-6 |
Storage
Solubility Information
DMSO: Insoluble
References and Literature
Related Products
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Enoxaparin sodium 679809-58-6 Proteases/Proteasome Thrombin traumatic brain injury infection coronavirus Inhibitor PK-10169 inhibit SARS-CoV Enoxaparin neuroprotective Liver fibrosis Fxa PK 10169 Inflammation PK10169 SARS coronavirus acute coronary syndromes Factor Xa Lovenox blood clots COVID-19 Thioacetamide inhibitor